STUDY
ATHEROGENIC LIPID PROFILE +/-INFLAMMATORY MARKERS
Estudios completados de lípidos GALAXY (1) y (2)
GALAXY LIPID STUDIES COMPLETED (1)
GALAXY LIPID STUDIES COMPLETED (2)
STELLAR
STELLARGALAXY LIPID STUDIES COMPLETED (1)
A 6-week, randomized, open-label study comparing the efficacy of specific doses and dosing interval of CRESTOR® with specific doses and dosing intervals of atorvastatin, pravastatin, and simvastatin in subjects with primary hypercholesterolemia1-8.
COMETS
COMETSGALAXY LIPID STUDIES COMPLETED (1)
A 12-week, randomized, double-blind, placebo-controlled, forced dose titration study to compare the efficacy of CRESTOR® 10 mg titrated to 20 mg with atorvastatin 10 mg titrated to 20 mg and placebo in the treatment of non-diabetic and non-atherosclerotic subjects with metabolic syndrome, elevated low-density lipoprotein cholesterol (LDL-C), and a 10-year coronary heart disease (CHD) risk of >10%9
MERCURY I
MERCURY IGALAXY LIPID STUDIES COMPLETED (2)
A 16-week, open-label, randomized study comparing the efficacy (percentage of patients achieving the European target and other lipid parameters) and safety after switching to the potential starting dose of CRESTOR® from accepted/possible starting doses of atorvastatin, pravastatin, and simvastatin in high-risk subjects with primary hypercholesterolemia10-17
MERCURY II
MERCURY IIGALAXY LIPID STUDIES COMPLETED (2)
A 16-week, randomized, open-label study comparing the efficacy (percentage of patients achieving NCEP ATP III target and other lipid parameters) and safety after switching to potential starting doses of CRESTOR® from accepted/possible starting doses of atorvastatin and simvastatin in high-risk subjects with primary hypercholesterolemia18-21
Estudios completados de lípidos GALAXY (3) y (4)
GALAXY LIPID STUDIES COMPLETED (3)
GALAXY LIPID STUDIES COMPLETED (4)
PULSAR
PULSARGALAXY LIPID STUDIES COMPLETED (3)
A 6-week, randomized, open-label study comparing the efficacy and safety of CRESTOR® 10 mg with atorvastatin 20 mg in subjects with hypercholesterolemia and a history of coronary heart disease or atherosclerosis or equivalent risk of coronary heart disease (10-year risk score of >20%).22-26
POLARIS
POLARISGALAXY LIPID STUDIES COMPLETED (3)
study comparing the efficacy and safety of CRESTOR® 40 mg with atorvastatin 80 mg in subjects with hypercholesterolemia and coronary heart disease or coronary heart disease equivalent risk (10-year risk score of >20%).27-29
ECLIPSE
ECLIPSEGALAXY LIPID STUDIES COMPLETED (4)
A 24-week, randomized, open-label study comparing the efficacy and safety of CRESTOR® 10-40 mg with atorvastatin 10-80 mg with forced titration for the treatment of patients with primary hypercholesterolemia and coronary heart disease or atherosclerosis or equivalent risk of coronary heart disease (10-year risk score of >20%). 30-33
EXPLORER
EXPLORERGALAXY LIPID STUDIES COMPLETED (4)
A 6-week randomized, open-label study to compare the efficacy and safety of CRESTOR® 40 mg in combination with ezetimibe 10 mg compared with CRESTOR® 40 mg in subjects with hypercholesterolemia and coronary heart disease or atherosclerosis or equivalent risk of coronary heart disease (10-year risk score of >20 %).34-38
Estudios completados de lípidos GALAXY (5) y (6)
GALAXY LIPID STUDIES COMPLETED (5)
GALAXY LIPID STUDIES COMPLETED (6)
CENTAURUS
CENTAURUSGALAXY LIPID STUDIES COMPLETED (5)
A 2-period, 3-month, randomized, multicenter, parallel-group study comparing the efficacy and safety of CRESTOR® 20 mg with atorvastatin 80 mg on ApoB/ApoA-I ratio and other lipid and inflammatory markers in subjects with acute coronary syndrome.39-40
DISCOVERY
DISCOVERYGALAXY LIPID STUDIES COMPLETED (5)
A 12-week, randomized, open-label study designed to evaluate the efficacy of CRESTOR® in achieving European LDL-C guideline targets and in modifying lipid parameters compared to atorvastatin (and other statins) to the recommended and approved starting dose in subjects with primary hypercholesterolemia.41-48
ORBITAL
ORBITALGALAXY LIPID STUDIES COMPLETED (6)
A 24-week, randomized, open-label study to compare the efficacy of CRESTOR® (10 mg titrated to 20 mg at 12 weeks, if necessary), in monotherapy or in combination with initiatives to improve patient compliance with regards to bringing subjects with primary hypercholesterolemia to European (and local) LDL-C guideline targets.49-51
PLUTO
PLUTOGALAXY LIPID STUDIES COMPLETED (6)
A 12-week, randomized, multicenter, placebo-controlled study with a 40-week open-label follow-up period to evaluate the efficacy and safety of CRESTOR® in pediatric subjects with heterozygous familial hypercholesterolemia.52
Estudios completados de lípidos GALAXY (7) y (8)
GALAXY LIPID STUDIES COMPLETED (7)
GALAXY LIPID STUDIES COMPLETED (8)
GRAVITY
GRAVITYGALAXY LIPID STUDIES COMPLETED (7)
A two-period, 12-week, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of CRESTOR® plus ezetimibe with simvastatin plus ezetimibe in hypercholesterolemic subjects with coronary heart disease or at high risk for it.53-54
MOON
MOONGALAXY LIPID STUDIES COMPLETED (7)
A 12-week, randomized, open-label study comparing CRESTOR® 20 mg or 40 mg with atorvastatin 80 mg on lipid parameters and pleiotropic effects in subjects with acute coronary syndromes.55-56
PLANET I
PLANET IGALAXY LIPID STUDIES COMPLETED (8)
A 12-month, randomized, double-blind, parallel-group study to evaluate the effects of CRESTOR® 10 mg and 40 mg and atorvastatin 80 mg on renal function using urine protein/creatinine ratio in diabetic subjects with moderate proteinuria. 57
PLANET II
PLANET IIGALAXY LIPID STUDIES COMPLETED (8)
A 12-month, randomized, double-blind, parallel-group study to evaluate the effects of CRESTOR® 10 mg and 40 mg, and atorvastatin 80 mg, on renal function using the urine protein/creatinine ratio in non-diabetic subjects with moderate proteinuria.57
References:
1-Jones P et al. Am J Cardiol 2003;92:152–160; 2-McKenney J et al. Curr Med Res Opin 2003;19:689–698; 3-Jones P et al. Clin Ther 2004;26:1388–1399; 4-Deedwania P et al. Am J Cardiol 2005;95:360–366; 5-Jones P et al. Atheroscler Suppl 2005; 6: 110 Abs W16-P-040; 6-Bays H et al. J Am Geriatr Soc 2004;52:S126; 7-Ballantyne C et al. Diabetalogia 2005;48:Abs 1083; 8-Asztalos BF et al. Am J Cardiol 2007;99(5):681–685; 9-Stalenhoef A et al. Eur Heart J 2005;26:2664–2672.10-Schuster H et al. Am Heart J 2004;147:705–712; 11-Stender S et al. Diabetes Obes Metab 2005;7:430–438; 12-Barter P et al. Atheroscler Suppl 2005; 6: 101 Abs W16-P-005; 13-Schuster H et al. Atheroscler Suppl 2005;6:121 Abs W16–P079; 14-Schuster H et al. Diabetalogia 2004;47(Suppl):1146 Abs AW09; 15-Cheung R et al. Int J Cardiol 2005;100: 309–316; 16-Schuster H et al. Diabetalogia 2005;48(Suppl 1):A391 Abs 1084; 17-Barter P et al. Int J Clin Pract 2005;59 (Suppl 148):6–7; 18-Ballantyne C et al. Am Heart J 2006;151:975e.1–975e; 19-Ballantyne C et al. Diabetalogia 2005; 48 (Suppl 1): Abs 1083; 20-Ballantyne C et al. Atheroscler Suppl 2005;6:101 Abs W16-P-003; 21-Ballantyne C et al. Atheroscler Suppl 2005;6:101 Abs W16-P-004. NCEP ATP III= National Cholesterol Education Programme Adult Treatment Panel III
22-Leiter LA et al. Atherosclerosis 2007;194:e.154–e.164; 23-Leiter LA et al. Diabetologia 2005;48(Suppl 1): A392 Abs 1085; 24-Miller PS et al. Value in Health 2005;8(6):A103 Abs PCV47; 25-Leiter LA et al. Atheroscler Suppl 2008;9(1):204; 26-Leiter LA et al. Atheroscler Suppl 2008;9(1):204; 27-Clearfield M et al. Trials 2006;7:35 doi:10.1186/1745-6215-7-35; 28-Clearfield M et al. Atheroscler Suppl 2008;9(1):199–200; 29-Clearfield MB et al. Atheroscler Suppl 2008;9(1):199–200. 30-Faergeman O et al. Atheroscler Suppl 2006;7:580 Abs Th-P16:394; 31-Faergeman O et al. Diabetologia 2006;49(Suppl 1):745 Abs 1235; 32-Faergeman O et al. Diab Med 2006;23(Suppl 4):301 Abs P824; 33-Faergeman O et al. Cardiology 2008;111 (4):219–228; 34-Ballantyne C et al. Am J Cardiol 2007;99(5):673–680; 35-Ballantyne C et al. Eur Heart J 2006;27(Suppl 1) Abs P5390; 36-Ballantyne C et al. Diabetologia 2006;49(Suppl 1):749 Abs 1240; 37-Ballantyne C et al. Diab Med 2006;23(Suppl 4):295 Abs P804; 38-Ballantyne CM et al. Atheroscler Suppl 2008;9(1):186.
39-Middleton A, Fuat A. Br J Cardiol 2006;13:72–76; 40-Strandberg T et al. Clin Ther 2004;26:1821–1833; 41-Fonseca FAH et al. Curr Med Res Opin 2005;21:1307–1315; 42-Gupta M et al. Atheroscler Suppl 2005;6:108 Abs W16-P-033; 43-Middleton A et al. Curr Med Res Opin 2006;22:1181–1191;44-Binbrek A et al. Curr Ther Res 2006;67:21–43; 7Bots A, Kastelein J. Int J Clin Pract 2005;59:1387–1394; 45-Herregods M et al. Acta Cardiologica 2006;61:235–236; 46-Lamotte M et al. Europrevent Abstract Book 2006; Abs 365; 10Zhu JR et al. Curr Med Res Opin 2007;23(12):3055–3068; 11Herregods M et al. Acta Cardiol 2008;63(4):493–499; 12Hu M et al. Atheroscler Suppl 2008;9(1):199; 47-Lablanche JM et al. Atheroscler Suppl 2006;7:578 (Abstract Th-P16: 384); 48-Lablanche JM et al. Arch Cardiovasc Dis 2008;101(6):399–406. ApoB = Apolipoproteina B, ApoA-I = Apolipoproteina AI
49-Willich SN et al. Am Heart J 2004;148:1060–1067; 50-Willich SN et al. Eur Heart J 2007;28(Suppl):212 (Abs P1364); 51-Willich SN et al. Eur J Cardiovasc Prev Rehabil 2009; doi:10.1097/HJR.0b03e3283262ac3; 52-Avis HJ et al. J Am Coll Cardiol 2009;doi:10.1016/j.jacc.2009.01.016.
53-Ballantyne C et al. Atheroscler Suppl 2008;9(1):186; 54-Ballantyne C, Schiebinger R; Cain, V. Randomized Comparison of Rosuvastatin Plus Ezetimibe Versus Simvastatin Plus Ezetimibe: results of the Gravity Study. J Am Coll Cardiol 2010;55 (10)Suppl 1: A49.E465. 55-Pitt B et al. J Am Coll Cardiol 2006;47(Suppl 1):323A; 56-Pitt B et al. J Am Coll Cardiol 2008;51(15):1440–1445. 57- Schuster H. Expert Rev Cardiovasc Ther 2007;5(2):177–193.
Exclusive material for health professionals. Produced by AstraZeneca CAMCAR Costa Rica S.A., Roble Corporate Center, 5th floor, Escazú, San José Costa Rica,phone: (506) 2201-3400, P.O. Box: 993-1260 Escazú. www.camcar.astrazeneca.com for AstraZeneca CAMCAR S.A. To report an adverse event, quality complaints ormedical information, visit: https://www.contactazmedical.astrazeneca.com CC-11139/November 2025